Safety and Efficacy of a First-Line Chemotherapy Tailored by G8 Score in Elderly Metastatic or Locally Advanced Gastric and Gastro-Esophageal Cancer Patients: A Real-World Analysis

被引:1
|
作者
Zurlo, Ina Valeria [1 ]
Pozzo, Carmelo [2 ]
Strippoli, Antonia [2 ]
Mignogna, Samantha [3 ]
Basso, Michele [2 ]
Vivolo, Raffaella [2 ]
Trovato, Giovanni [2 ]
Ciaburri, Michele [4 ]
Morelli, Franco [3 ]
Bria, Emilio [2 ]
Leo, Silvana [1 ]
Tortora, Giampaolo [2 ]
机构
[1] Vito Fazzi Hosp, Med Oncol Unit, I-73100 Lecce, Italy
[2] Fdn Policlin Univ A Gemelli IRCCS, Comprehens Canc Ctr, Med Oncol Unit, I-00168 Rome, Italy
[3] Gemelli Molise, Med Oncol Unit, I-86100 Campobasso, Italy
[4] Fdn Policlin Univ A Gemelli IRCCS, Geriatr Unit, I-00168 Rome, Italy
关键词
gastric cancer; elderly; toxicity; G8; score; comprehensive geriatric assessment; COMPREHENSIVE GERIATRIC ASSESSMENT; OLDER PATIENTS; PHASE-III; SCREENING TOOLS; CLINICAL-TRIALS; AGE; PARTICIPATION; COMORBIDITY; PERFORMANCE; ENROLLMENT;
D O I
10.3390/geriatrics7050107
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Introduction: Gastric (GC) and gastro-esophageal cancer (GEC) are common neoplasms in the elderly. However, in clinical practice, the correct strategy for elderly patients who might benefit from chemotherapy (CT) is unknown. Prospective data are still poor. In this context, we performed a retrospective analysis of GC patients aged >= 75 years and treated at our institutions. Material and Methods: We retrospectively analyzed 90 patients with confirmed metastatic GC or GEC, treated with an upfront CT. Inclusion criteria were patients aged >= 75 years, PS 0-2, normal bone marrow/liver/renal function and no major comorbidities. All patients received a G8 score, and some patients with G8 <= 14 received a comprehensive geriatric assessment (CGA). The primary goal was to perform a safety evaluation based on the incidence of adverse events (AE), and the secondary goal was to determine the efficacy (PFS and OS). The chi-square test and the Kaplan-Meier method were used to estimate the outcomes. The statistical significance level was set at p < 0.05. Results: Toxicity rates were quite low: G1/G2 (51.1%) and G3/G4 (25.5%). No toxic deaths were reported. The median PFS was 6.21 months and the median OS 11 months. The G8 score and PS ECOG significantly influenced both PFS and OS. A statistically significant correlation among G8, weight loss, hypoalbuminemia and risk of G3/G4 adverse events was also found. Conclusion: Our research on selected elderly patients did not detect broad differences of efficacy and tolerability compared to a young population. Our study, although retrospective and small-sized, showed that G8 score might be an accurate tool to identify elderly GC/GEC patients who could be safely treated with CT, further recognizing patients who could receive a doublet CT and who may require a single agent chemotherapy or a baseline dose reduction.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Real-World Treatment Patterns and Economic Burden Following First-Line Trastuzumab in Patients with Metastatic Gastric Cancer in the USA
    Afsaneh Barzi
    Feng Lin
    Jinlin Song
    Clara Lam
    Xiaoyu Nie
    Ahmed Noman
    Winghan J. Kwong
    [J]. Drugs - Real World Outcomes, 2023, 10 : 395 - 404
  • [22] Real-World Treatment Patterns and Economic Burden Following First-Line Trastuzumab in Patients with Metastatic Gastric Cancer in the USA
    Barzi, Afsaneh
    Lin, Feng
    Song, Jinlin
    Lam, Clara
    Nie, Xiaoyu
    Noman, Ahmed
    Kwong, Winghan J.
    [J]. DRUGS-REAL WORLD OUTCOMES, 2023, 10 (03) : 395 - 404
  • [23] Real-World Study of Patients With EGFR Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer Treated With First-Line Osimertinib
    Nieva, J.
    Taylor, A.
    Servidio, L.
    Sun, P.
    Okhuoya, P.
    Horvat, P.
    Tolani, E.
    Magee, K.
    Mathur, R.
    Balakrishna, S.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1113 - S1113
  • [24] Efficacy and safety of first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a meta-analysis
    Wang Ming
    Zheng Xiaofeng
    Ruan Xiaojiao
    Ye Bailiang
    Cai Long
    Lin Feizhuan
    Tu Jinfu
    Jiang Feizhao
    Li Shaotang
    [J]. CHINESE MEDICAL JOURNAL, 2014, 127 (03) : 538 - 546
  • [25] Overall survival and treatment patterns among real-world patients with locally advanced or metastatic urothelial carcinoma treated with first-line therapy
    Simeone, Jason C.
    Nordstrom, Beth L.
    Patel, Ketan
    Klein, Alyssa B.
    Horne, Laura
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [26] Safety and efficacy of tislelizumab plus chemotherapy versus chemotherapy alone as neoadjuvant treatment for patients with locally advanced gastric cancer: real-world experience with a consecutive patient cohort
    Jiang, Qi
    Liu, Weizhen
    Zeng, Xiangyu
    Zhang, Chenggang
    Du, Yuqiang
    Zeng, Liwu
    Yin, Yuping
    Fan, Jun
    Yang, Ming
    Tao, Kaixiong
    Zhang, Peng
    [J]. FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [27] Efficacy and Safety of Niraparib as First-Line Maintenance Treatment for Patients with Advanced Ovarian Cancer: Real-World Data from a Multicenter Study in China
    Zhao, Minmin
    Qiu, Shanhu
    Wu, Xin
    Miao, Pengcheng
    Jiang, Zhi
    Zhu, Tao
    Xu, Xizhong
    Zhu, Yanling
    Zhang, Bei
    Yuan, Donglan
    Zhang, Yang
    Sun, Wei
    He, Aiqin
    Zhao, Min
    Hou, Wenjie
    Zhang, Yingli
    Shao, Zhuyan
    Jia, Meiqun
    Li, Mei
    Chen, Jun
    Xu, Jingcheng
    Chen, Bingwei
    Zhou, Ying
    Shen, Yang
    [J]. TARGETED ONCOLOGY, 2023, 18 (06) : 869 - 883
  • [28] Efficacy and Safety of Niraparib as First-Line Maintenance Treatment for Patients with Advanced Ovarian Cancer: Real-World Data from a Multicenter Study in China
    Minmin Zhao
    Shanhu Qiu
    Xin Wu
    Pengcheng Miao
    Zhi Jiang
    Tao Zhu
    Xizhong Xu
    Yanling Zhu
    Bei Zhang
    Donglan Yuan
    Yang Zhang
    Wei Sun
    Aiqin He
    Min Zhao
    Wenjie Hou
    Yingli Zhang
    Zhuyan Shao
    Meiqun Jia
    Mei Li
    Jun Chen
    Jingcheng Xu
    Bingwei Chen
    Ying Zhou
    Yang Shen
    [J]. Targeted Oncology, 2023, 18 : 869 - 883
  • [29] A retrospective real-world study of nimotuzumab combined with chemotherapy for first-line treatment of advanced pancreatic cancer: A single center propensity score matched analysis
    Wu, Y.
    Dong, X.
    Li, E.
    Fan, Y.
    Dong, D.
    Shi, Y.
    Wang, M.
    Yang, N.
    Ou, F.
    Wang, J.
    Yang, Y.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S920 - S920
  • [30] A multicenter phase II study of biweekly capecitabine in combination with oxaliplatin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer
    Yee Chao
    Jan-Sing Hsieh
    Hsien-Tang Yeh
    Yu-Chieh Su
    Cheng-Chung Wu
    Jen-Shi Chen
    Cheng-Jeng Tai
    Li-Yuan Bai
    Kun-Huei Yeh
    Wu-Chou Su
    Chung-Pin Li
    [J]. Cancer Chemotherapy and Pharmacology, 2014, 73 : 799 - 806